Juno Therapeutics (JUNO) IPO Opens Up 63%

Today's IPO for Juno Therapeutics (NASDAQ: JUNO) opened for trading at $39 after pricing 11,022,917 shares of common stock at a price to the public of $24 per share, above the expected $21-$23 range which was recently raised from $15-$18. The number of shares offered was raised from 9,250,000 shares.

Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. are acting as lead book-running managers for the offering. Leerink Partners LLC is acting as a co-manager.

Juno Therapeutics, Inc. is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

You May Also Be Interested In

• Senate Committee Investigates Ozempic and Wegovy Costs - NYT
• Tesla (TSLA) erases gains, drops to $140 again
• B. Riley Financial (RILY) touching day low of $27, giving back half the day's gains